Abstract
The study compares the efficacy of risperidone and haloperidol in patients of schizophrenia on various clinical and psychosocial parameters.
In the present open, comparative study, in patients suffering from schizophrenia (DSM-IV), 50 patients each were randomly treated with risperidone and haloperidol over a period of 1 year. The clinical improvement was judged on PANSS (Positive and Negative Symptom Scale) and CGIS (Clinical Global Impression Scale). The improvement in psychosocial functioning and other areas was judged using a five point scale (0-4). Though the improvement on PANSS was comparable in both the groups except on the general psychopathology subscale, on CGIS a better improvement profile was observed in risperidone group. In the other psychosocial areas such as social functioning, productivity and education a significantly more number of patients showed improvement in risperidone group as compared to haloperidol group. In significantly less number of patients suicidality and rehospitalization was found in risperidone group as compared to haloperidol group.
Keywords: Risperidone, haloperidol, social integration, quality of life
Full Text
The Full Text of this article is available as a PDF (200.6 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bech P., Angst J. Quality of life in anxiety and social phobia. Int Clin Psychopharmacol. 1996 Jun;11 (Suppl 3):97–100. doi: 10.1097/00004850-199606003-00016. [DOI] [PubMed] [Google Scholar]
- Carman J., Peuskens J., Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol. 1995 Nov;10(4):207–213. doi: 10.1097/00004850-199511000-00001. [DOI] [PubMed] [Google Scholar]
- Cesková E., Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry. 1993 Jul;26(4):121–124. [PubMed] [Google Scholar]
- Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G. W., Labelle A., Beauclair L., Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993 Feb;13(1):25–40. [PubMed] [Google Scholar]
- Claus A., Bollen J., De Cuyper H., Eneman M., Malfroid M., Peuskens J., Heylen S. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand. 1992 Apr;85(4):295–305. doi: 10.1111/j.1600-0447.1992.tb01473.x. [DOI] [PubMed] [Google Scholar]
- Kay S. R., Fiszbein A., Opler L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. doi: 10.1093/schbul/13.2.261. [DOI] [PubMed] [Google Scholar]
- Marder S. R., Meibach R. C. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994 Jun;151(6):825–835. doi: 10.1176/ajp.151.6.825. [DOI] [PubMed] [Google Scholar]